KIDS ORTHOPEDIATRICS CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1425450 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.1%
TTM net income YoY25.7%
TTM EPS YoY27.6%
Revenue 3-yr CAGR23.0%
Net income 3-yr CAGR—
Margins
Gross margin73.8%
Operating margin-9.4%
Net margin-12.8%
FCF margin1.2%
EBITDA margin-0.8%
Returns
ROE-9.8%
ROA-6.8%
ROIC (approx.)-4.6%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets33.3%
Debt / equity0.30x
Current ratio4.55x
Interest coverage-2.70x
Cash quality & payout
Operating cash flow / net income-0.37x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $72.66M | $70.51M | $59.36M | $61.60M | $61.25M | $61.08M | $52.41M | $52.67M |
| Cost of revenue | $18.68M | $18.14M | $15.97M | $16.50M | $15.98M | $17.06M | $14.15M | $17.10M |
| Gross profit | $53.98M | $52.37M | $43.39M | $45.11M | $45.27M | $44.02M | $38.26M | $35.56M |
| R&D expense | $2.46M | $2.33M | $2.23M | $2.26M | $2.33M | $2.16M | $2.35M | $2.92M |
| SG&A expense | $32.03M | $32.81M | $31.02M | $29.95M | $29.16M | $30.44M | $30.28M | $24.43M |
| Operating income | -$4.22M | -$4.07M | -$8.34M | -$8.17M | -$9.43M | -$10.66M | -$10.98M | -$14.05M |
| Interest expense | $2.62M | $2.53M | $2.10M | $1.93M | $1.82M | $1.12M | $1.13M | $1.32M |
| Pretax income | -$6.04M | -$6.93M | -$10.86M | -$9.76M | -$11.90M | -$7.06M | -$10.46M | -$16.41M |
| Income tax | -$109,000 | $234,000 | -$171,000 | $340,000 | -$125,000 | $49,000 | $196,000 | -$340,000 |
| Net income | -$5.93M | -$7.16M | -$10.69M | -$10.10M | -$11.77M | -$7.11M | -$10.66M | -$16.07M |
| EBITDA | $1.40M | $1.64M | -$2.61M | -$2.57M | -$4.13M | -$5.49M | -$5.93M | -$10.06M |
| EPS (basic) | -0.25 | -0.30 | -0.45 | — | -0.50 | -0.30 | -0.46 | — |
| EPS (diluted) | -0.25 | -0.30 | -0.45 | — | -0.50 | -0.30 | -0.46 | — |
| Weighted avg. shares (diluted) | 24.15M | 24.05M | 23.69M | — | 23.57M | 23.46M | 23.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17.14M | $17.00M | $12.19M | $19.56M | $18.88M | $46.60M | $35.43M | $45.78M |
| Short-term investments | $27.09M | $28.88M | $36.62M | $41.30M | $40.90M | $25.60M | $25.33M | $25.01M |
| Receivables | $59.54M | $60.95M | $54.43M | $53.84M | $51.27M | $53.80M | $43.99M | $42.36M |
| Inventory | $141.86M | $137.57M | $134.02M | $133.79M | $128.81M | $125.27M | $119.75M | $117.00M |
| Current assets | $253.24M | $252.51M | $245.87M | $256.42M | $245.85M | $257.70M | $232.06M | $237.17M |
| PP&E, net | $46.94M | $48.55M | $48.55M | $49.55M | $51.20M | $52.93M | $52.62M | $50.60M |
| Goodwill | $118.59M | $118.46M | $115.17M | $109.27M | $103.61M | $99.02M | $93.67M | $93.84M |
| Intangibles | $61.67M | $63.74M | $63.80M | $64.80M | $63.26M | $62.95M | $62.35M | $64.43M |
| Total assets | $509.09M | $511.39M | $502.19M | $508.63M | $493.49M | $503.61M | $470.25M | $473.21M |
| Current liabilities | $55.63M | $52.85M | $47.18M | $46.20M | $33.23M | $38.67M | $37.51M | $33.96M |
| Short-term debt | $2.94M | $2.53M | $2.22M | $1.87M | $1.53M | $838,000 | $896,000 | $897,000 |
| Long-term debt | $98.19M | $99.46M | $100.39M | $99.82M | $99.17M | $97.00M | $73.03M | $72.96M |
| Total debt | $101.13M | $101.99M | $102.61M | $101.68M | $100.70M | $97.84M | $73.92M | $73.85M |
| Total liabilities | $169.74M | $167.77M | $163.48M | $162.03M | $144.18M | $148.09M | $123.10M | $118.64M |
| Shareholders' equity | $339.35M | $343.61M | $338.71M | $346.60M | $349.31M | $355.51M | $347.15M | $354.57M |
| Net debt | $83.98M | $84.99M | $90.42M | $82.13M | $81.82M | $51.24M | $38.49M | $28.08M |
| Shares outstanding | — | — | — | 25.09M | — | — | — | 24.22M |
| Cash flow statement | ||||||||
| Operating cash flow | $4.51M | $928,000 | -$3.29M | $10.35M | -$581,000 | -$10.46M | -$4.16M | -$3.99M |
| Capital expenditure | $2.91M | $4.04M | $1.76M | $599,000 | $2.84M | $3.44M | $4.23M | -$262,000 |
| Free cash flow | $1.59M | -$3.12M | -$5.05M | $9.75M | -$3.42M | -$13.91M | -$8.38M | -$3.73M |
| Investing cash flow | -$4.15M | $5.00M | -$3.79M | -$7.26M | -$26.84M | -$3.54M | -$5.99M | -$2.41M |
| Financing cash flow | -$1.53M | -$737,000 | -$614,000 | -$417,000 | -$282,000 | $24.80M | -$126,000 | -$541,000 |
| Depreciation & amortization | $5.62M | $5.71M | $5.72M | $5.60M | $5.30M | $5.17M | $5.05M | $3.99M |
| Stock-based compensation | $4.42M | $4.19M | $3.98M | $4.42M | $4.25M | $5.25M | $3.86M | $3.89M |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.